Better Health for All

Rapport Therapeutics is a clinical-stage biopharmaceutical company, formed in February 2022, focused on developing precision medicines for neurological disorders.

Its lead product candidate, RAP-219, is being developed for drug-resistant focal epilepsy, peripheral neuropathic pain, and bipolar disorder. In a Phase 2a trial for focal epilepsy, 85.2% of patients achieved a >=30% reduction in long episodes, 72.0% achieved a >=50% reduction in clinical seizures, and 24% achieved seizure freedom, demonstrating exceptional health benefits. As a clinical-stage company, it has zero revenue from any products, and its business model is exclusively designed for maximizing health benefits. The company launched with $100 million in Series A financing and had a cash position of $320.7 million as of September 30, 2024, expected to fund operations through the end of 2026, indicating substantial investment in health innovation. The IP for RAP-219 expires in 2036, and the company is subject to substantial contingent payments to Janssen, suggesting limited patent flexibility. In Phase 1 trials, 3% of 100 healthy volunteers discontinued treatment due to adverse events. In the Phase 2a trial, 10% of 30 patients discontinued due to treatment-emergent adverse events (TEAEs), with 78.5% of TEAEs being mild and 21.5% moderate, and no serious adverse events reported. The company plans to enroll adult patients with drug-resistant focal epilepsy, a vulnerable population, and is evaluating RAP-219 for bipolar mania. The company relies on third-party service providers for data collection and processing, and its ability to monitor their information security practices is limited. The company's Code of Business Conduct and Ethics, adopted May 29, 2024, outlines policies for compliance, confidentiality, and accurate public disclosures, but also contains forward-looking statements and disclaimers regarding risks and uncertainties.

Fair Money & Economic Opportunity

Rapport Therapeutics, Inc. is a biopharmaceutical company.

The 'Fair Money & Economic Opportunity' value and its associated KPIs are designed to assess financial institutions and their provision of lending, deposit, and other financial services to consumers. The provided articles do not contain any evidence that Rapport Therapeutics, Inc. offers such financial products or services. Therefore, all KPIs related to consumer financial services, including underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility for financial data, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion for banking services, and product simplicity for financial products, are not applicable to the company's core business.

Fair Pay & Worker Respect

Rapport Therapeutics reports that women are paid, on average, 101% of male salaries for jobs at the same level.

The company conducts an annual pay equity analysis and shares salary ranges internally. No material labor dispute with employees exists or is imminent. The company's Code of Business Conduct and Ethics, effective May 29, 2024, explicitly protects employees' rights to file complaints with government agencies, communicate with agencies, participate in investigations, exercise rights under the National Labor Relations Act, share compensation information, discuss unlawful acts, and receive whistleblower awards, while forbidding retaliation for good faith reporting. An executive employment agreement indicates eligibility for health insurance, with COBRA continuation for 12 months in certain termination scenarios. However, there is no information on the percentage of the total workforce covered by employer-funded health insurance.

Fair Trade & Ethical Sourcing

The provided articles, primarily financial reports and a code of business conduct, do not contain any specific, quantitative, or actionable information regarding Rapport Therapeutics, Inc.'s fair trade and ethical sourcing practices.

There is no evidence found for fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, spend on high-risk materials, or supplier diversity spend.

Kind to Animals

The company utilizes animal models for preclinical activity, specifically mentioning their use in third-party pain models and for assessing pain behavior improvements in animal models of acute, inflammatory, and neuropathic pain.

This indicates that traditional animal assays are a significant part of their testing methodology.

Planet-Friendly Business

The provided articles, consisting primarily of SEC filings and company overviews, focus on financial performance, corporate governance, and scientific pipeline. They do not contain specific, quantifiable data or explicit statements regarding Rapport Therapeutics, Inc.'s environmental performance across any of the defined Planet-Friendly Business KPIs.

Therefore, no KPIs can be scored based on the evidence provided.

Zero Waste & Sustainable Products

Rapport Therapeutics' operations involve the use of hazardous and flammable materials, including chemicals and biological materials, which produce hazardous waste products.

The company contracts with third parties for the disposal of these materials and wastes, indicating a compliant and industry-standard approach to hazardous waste handling.